Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
29 082 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE V XXXXXXXXX PRAVOMOCI (XX) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx xx xxx účely xxxxxxxxxxxx xxxxxxxxxxx x vědeckému xxxxxxx xxxx xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, označování a xxxxxx látek x xxxxx

(Xxxx x významem xxx EHP)

EVROPSKÁ XXXXXX,

x xxxxxxx na Smlouvu x xxxxxxxxx Evropské xxxx,

x xxxxxxx xx xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. prosince 2008 o xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx a xxxxx, x xxxxx x xxxxxxx xxxxxxx 67/548/EHS x 1999/45/XX x x xxxxx xxxxxxxx (XX) x. 1907/2006 (1), x xxxxxxx xx xx. 37 xxxx. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (ES) č. 1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx látek xx xxxxxxx kritérií xxxxxxxxxxx v částech 2 až 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x článkem 37 xxxxxxxx (XX) č. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx klasifikací a xxxxxxxx některých jiných xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx vydal Xxxxx xxx posuzování xxxxx („RAC“) xxxxxxxx, xxxxx i xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx zrušit harmonizované xxxxxxxxxxx x označení xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru XXX xxxx:

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx vláken x xxxxxxx křemíku (o xxxxxxx < 3 μx,xxxxx &xx; 5 μx a xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko ze xxx 14. xxxx 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx acyloxy) derivátů [2],

—

xxxxxxxxxx ze dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (XXX), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—

stanovisko xx dne 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx 2,2-bis(brommethyl)propan-1,3-diolu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko ze xxx 28. ledna 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-onu, flupyradifuronu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylátu,

—

stanovisko xx xxx 9. března 2018 xxxxxxx L-(+)-mléčné xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx kyseliny,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanonu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx 2-methyl-1,2-benzothiazol-3(2H)-onu, [XXXX],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. října 2018 ohledně 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, penflufenu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), isopropyl [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [olej xxxxxxxx za xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx pirimifos-methylu (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko ze 30. xxxxxxxxx 2018 xxxxxxx fosfinu,

—

stanovisko xx xxx 14. září 2018 ohledně xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx olova,

—

stanovisko xx xxx 14. xxxx 2018 ohledně 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (ISO), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx azoxystrobinu (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 30. listopadu 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx hymexazolu (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx hexythiazoxu (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. března 2018 ohledně xxxxxxxxxxxx (XXX), reakční směsi: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx rozvětveného xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, hexyl 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x látku xxxxx (číslo XXX 7439–92–1 x xxxxxxxx xxxxx 082–013–00–1 (xxxxx x prášku; [průměr xxxxxx < 1 xx];) a 082–014–00–7 (xxxxxxxx xxxxx; [průměr xxxxxx ≥ 1 xx];)), RAC xx xxxx stanovisku ze xxx 30. xxxxxxxxx 2018 navrhl xxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx x xxxxxxxxx formu. Xxxxx xxxxxxxx x nižší xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, xx specifické xxxxxxx xxxxxx xxxxxx x vzhledem k xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxx xxxxx jiných xxxx v existujících xxxxxxxxx v xxxxxxx XX xxxx XXX xxxxxxx další xxxxxxxxx xxxx, xxx xx xxx na celistvou x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx byly předloženy xxxx xxxxxxx poznatky, x nichž xxxxxxx, xx xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx, xxx ji xxxxxxxxxx xxxxxxxxxx xxxxxx XXX, xxxxxx xxx vhodná. Xxxxxxxxxxxxxxx klasifikace pro xxxxxxxxx xxxxx xxxxx xxxxxx zařazena xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx RAC xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (číslo XXX 111-76-2), pro xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ byly předloženy xxxx vědecké xxxxxxxx, xx kterých xxxxxxx, xx xxxxxxxxxxx xxx xxxx třídu nebezpečnosti xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx XXX, xxx xx zakládá na xxxxxxxx xxxxxxx, nemusí xxx xxxxxx. Xxxx xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x xxxxxxx VI xxxxxxxx (ES) x. 1272/2008 změněna, xxxxx XXX xxxxxx xxx xxxxxxx xxxxxxxxx x xxxxx xxxxx informacím xxxxxxxxxx stanovisko; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx výboru XXX, xx zařazeny být xxxx.

(5)

Xxxxxxxx (ES) č. 1272/2008 xx proto xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx by xxxxxx xxx, s xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx ihned, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx xx xx, xxx xxxxxxxxxxxx xxxxxxxxxx x balení xxxxx x směsí novým xxxx revidovaným xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Xxxx xxxx xx xxxxxx xxxxxxxx x tomu, xxx xxxxxxxxxx xxxx dostatek xxxx xxxxxxxx xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx dodržování xxxxxxx xxxxxxxx požadavků, xxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx podle xxxxxx nařízení. Xxxx xxxxxxxxx mohou zahrnovat xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 písm. x) xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1907/2006 (3) xxxx xxxxxxxxx xxxxxxxxx v xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by však xxxx xxx xxxxxxxx, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx. Xx xx v souladu x xxxxxxxxx podle xx. 61 odst. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Změny xxxxxxxx (XX) č. 1272/2008

Xxxxxxx 3 v xxxxx 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xx xxxx x souladu x xxxxxxxx tohoto nařízení.

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx xxxx xx vyhlášení v Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx se xxx xxx 1. března 2022.

Xxxxxxxx od xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx být xxxxx x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x baleny x xxxxxxx x xxxxxxxxx (ES) x. 1272/2008 xx znění xxxxxx nařízení xxxxx xxxxx xxxx 1. xxxxxx 2022.

Xxxx xxxxxxxx xx xxxxxxx x celém xxxxxxx x přímo xxxxxxxxxx ve xxxxx xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. xxxxxx 2020.

Xx Komisi

Ursula VON XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. věst. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx jsou xxxxxxxx na xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (ES) č. 1907/2006 xx xxx 18. prosince 2006

x xxxxxxxxxx, xxxxxxxxx, povolování x xxxxxxxxx xxxxxxxxxx xxxxx, o xxxxxxx Xxxxxxxx agentury xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/XX x o xxxxxxx xxxxxxxx Rady (XXX) x. 793/93, xxxxxxxx Xxxxxx (ES) č. 1488/94, směrnice Xxxx 76/769/XXX a xxxxxxx Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX x 2000/21/ES (Xx. věst. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x dodávání xxxxxxxxxx xxxxxxxxx na xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, x. 1).

PŘÍLOHA

V xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx tabulka 3 x xxxxx 3 mění xxxxx:

1)

Xxxxxxxx xx xxxx položky:

Indexové xxxxx

Xxxxxxxx název

Číslo XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx a xxxxxxxxx nebezpečnosti

Kódy xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Liq. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (páry)

Skin Xxxx. 1 A; X314: X ≥ 20 %

Xxxx Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx křemíku (x průměru &xx; 3 μx, xxxxx &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; trimethoxy(vinyl)silan

220-449-8

2768-02-7

Skin Sens. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

STOT SE 3

XXXX XX 1

Xxx Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X225

X331

X301

X336

X370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 mg/l (páry)

orální: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx částic: od 0,9 mm x xx 6,0 mm; xxxxx xxxxxx: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Chronic 2

H411

GHS09

H411“

„029-025-00-5

bis(N-hydroxy-N-nitrosocyklohexylaminato-O,O’)měď;

bis(N-cyklohexyl-diazenium-dioxy)-měď;

[Cu-HDO]

239-703-4

312600-89-8

15627-09-5

Flam. Xxx. 1

Xxxxx Tox. 4

XXXX XX 2

Xxx Xxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, bis(koko acyloxy) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Repr. 1X

XXXX XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1B; X350: C ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Tox. 4

STOT XX 2

Aquatic Chronic 1

X360X

X302

X373 (xxx, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

bis(2-(2-methoxyethoxy)ethyl)-ether; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Acute Xxx. 4

Xxxxx Tox. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 mg/kg XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (ISO);

S-ethyl (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Xxx. 4

XXXX RE. 2

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: ATE = 450 mg/kg XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX RE 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 xx/xx TH

M = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Repr. 1B

Acute Xxx. 3

Acute Xxx. 4

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 mg/l (páry)

orální: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx kyselina …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1B

Muta. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX SE 3

Xxxx Irrit. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (xxxxx xxxx mlha)

orální: ATE = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Xxxxx Xxx. 3

STOT XX 2

Xxxx Irrit. 2

Eye Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Corr. 1

Xxx Dam. 1

Aquatic Xxxxx 1

Aquatic Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2RS)-2-[4-(4-chlorfenoxy)-2-(trifluormethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;

mefentriflukonazol

–

1417782-03-6

Skin Xxxx. 1

Aquatic Acute 1

Xxxxxxx Chronic 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

XXXX XX 1

Xxx Xxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: ATE = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Tox. 4

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 mg/kg XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Tox. 2

Xxxxx Tox. 4

Skin Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H330

H302

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H314

H317

H410

EUH071

inhalační: XXX = 0,16 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ C &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; H317: X ≥ 0,0015 %

M = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Tox. 4

Xxxxx Xxx. 3

Skin Xxxx. 1X

Xxx Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx XX

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; methylolakrylamid; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

H351

GHS08

Wng

H351“

„616-233-00-1

silthiofam (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX RE 2

Xxxxxxx Xxxxxxx 2

H373

H411

GHS08

GHS09

Wng

H373

H411“

„650-057-00-6

Margosa, xxxxxxx [xxxx lisovaný xx xxxxxxx xx semen xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

X412

X412“

2)

xxxxxxx odpovídající xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx a XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx x nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx a xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx dusičná …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Acute Xxx. 1

Skin Xxxx. 1 A

H272

H330

H314

GHS03

GHS06

GHS05

Dgr

H272

H330

H314

EUH071

Ox. Liq. 2; X272: C ≥ 99 %

Ox. Xxx. 3; X272: 70 % ≤ X < 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

pirimifos-methyl (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H302

H372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1 000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Gas 1

Press. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1B

Acute Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxxxx 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 D: X ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-ethyl-4,4-dioktyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradekanoát; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Aquatic Xxxxx 1

Aquatic Chronic 1

X360X

X372 (imunitní systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx prášek; [xxxxxx xxxxxx &xx; 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX H362

H410

Repr. 1 X; X360X: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxx Sens. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 xx/xx XX orální: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

M = 10“

„607-314-00-2

ethofumesát (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-dinitrofenol

200-087-7

51-28-5

Acute Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Tox. 2

XXXX RE 1

Aquatic Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: XXX = 300 mg/kg XX xxxxxx: ATE = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X361x

X373 (xxx, xxxxxxx systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, nervový systém)

H410

M = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [OIT]

247-761-7

26530-20-1

Acute Xxx. 2

Xxxxx Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach nebo xxxx)

xxxxxxxx: XXX = 311 xx/xx XX xxxxxx: XXX = 125 mg/kg XX

Xxxx Xxxx. 1 A; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Acute Xxx. 4

Xxx Dam. 1

Skin Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 mg/kg XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

pymetrozin (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx směs: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (xxxxxxx xxxxxx; orální, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Xxx. 4

Acute Xxx. 3

STOT SE 3

XXXX XX 1

XXXX XX 2

Skin Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

H350

H312

H301

H336

H370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní dýchací xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1 100 xx/xx XX xxxxxx: XXX = 100 xx/xx TH“

„617-006-00-X

bis(α,α-dimethylbenzyl)peroxid

201-279-3

80-43-3

Org. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxxxxx Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.